Fabian Lohaus

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9117253/publications.pdf

Version: 2024-02-01

50	1,941	279487	253896
papers	citations	23 h-index	43 g-index

54	54	54	3563
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomographyâ€“staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. European Urology Oncology, 2022, 5, 44-51.	2.6	26
2	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. Radiotherapy and Oncology, 2022, 167, 300-307.	0.3	5
3	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC â€“ Hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiotherapy and Oncology, 2022, 169, 8-14.	0.3	5
4	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.3	4
5	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). Cancers, 2022, 14, 2073.	1.7	7
6	A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers, 2022, 14, 3031.	1.7	2
7	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics Journal, 2021, 21, 37-46.	0.9	6
8	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. Clinical and Translational Radiation Oncology, 2021, 26, 62-70.	0.9	8
9	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the â€˜TOaSTTâ€™ database. Radiation Oncology, 2021, 16, 4.	1.2	20
10	Altered brain responses to emotional facial expressions in tinnitus patients. Progress in Brain Research, 2021, 262, 189-207.	0.9	2
11	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics, 2021, 11, 7844-7868.	4.6	70
12	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiation Oncology, 2021, 16, 141.	1.2	9
13	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. Cancers, 2021, 13, 4780.	1.7	8
14	Tumor DNAâ€Methylome derived Epigenetic Fingerprint Identifies HPV â€negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. International Journal of Cancer, 2021, 150, 603.	2.3	2
15	Quantification of plan robustness against different uncertainty sources for classical and anatomical robust optimized treatment plans in head and neck cancer proton therapy. British Journal of Radiology, 2020, 93, 20190573.	1.0	7
16	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Scientific Reports, 2020, 10, 15625.	1.6	34
17	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. Cancers, 2020, 12, 3047.	1.7	19
18	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy. Radiation Oncology, 2020, 15, 135.	1.2	8

#	Article	IF	Citations
19	Comparison of GeneChip, nCounter, and Real-Time PCRâ€“Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Molecular Diagnostics, 2020, 22, 801-810.	1.2	10
20	Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response. Frontiers in Oncology, 2020, 10, 627379.	1.3	24
21	Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. Clinical Lung Cancer, 2019, 20, e667-e677.	1.1	33
22	Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus ZÃ¶phel, Steffen LÃ¶ck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548â€“51. European Urology, 2019, 76, e103-e104.	0.9	0
23	Including anatomical variations in robust optimization for head and neck proton therapy can reduce the need of adaptation. Radiotherapy and Oncology, 2019, 131, 127-134.	0.3	42
24	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clinical Cancer Research, 2019, 25, 3152-3163.	3.2	53
25	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. Clinical and Translational Radiation Oncology, 2019, 16, 40-47.	0.9	32
26	Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma. Radiotherapy and Oncology, 2019, 133, 28-34.	0.3	8
27	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. European Journal of Cancer, 2019, 110, 11-20.	1.3	44
28	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. European Urology, 2019, 75, 548-551.	0.9	36
29	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiotherapy and Oncology, 2018, 127, 27-35.	0.3	17
30	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clinical Cancer Research, 2018, 24, 1364-1374.	3.2	45
31	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.3	24
32	Heat shock protein 70 and tumorâ€infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTKâ€ROG). International Journal of Cancer, 2018, 142, 1911-1925.	2.3	50
33	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	1.2	34
34	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer, 2017, 141, 594-603.	2.3	91
35	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. Scientific Reports, 2017, 7, 13206.	1.6	163
36	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clinical and Translational Radiation Oncology, 2017, 5, 28-36.	0.9	16

#	Article	IF	Citations
37	Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. International Journal of Radiation Oncology Biology Physics, 2017, 98, 511-520.	0.4	42
38	Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinomaâ€"a multicenter analysis of the German working group â€œStereotactic Radiotherapyâ€• Journal of Thoracic Disease, 2017, 9, 4512-4522.	0.6	43
39	Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes. Radiation Oncology, 2017, 12, 190.	1.2	25
40	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130
41	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. Clinical and Translational Radiation Oncology, 2016, 1, 19-26.	0.9	22
42	Evaluation of a deformable registration algorithm for subsequent lung computed tomography imaging during radiochemotherapy. Medical Physics, 2016, 43, 5028-5039.	1.6	9
43	Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastasesâ€"A pooled analysis of the German working group â€œstereotactic radiotherapyâ€• Lung Cancer, 2016, 97, 51-58.	0.9	128
44	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â^') HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
45	Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 94, 841-849.	0.4	19
46	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). International Journal of Cancer, 2016, 138, 171-181.	2.3	184
47	Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiotherapy and Oncology, 2016, 118, 485-491.	0.3	101
48	Corrigendum to â€œHPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)â€• [Radiother. Oncol. 113 (2014) 317â€"323]. Radiotherapy and Oncology, 2015, 114, 419.	0.3	0
49	HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC. Annals of Translational Medicine, 2015, 3, 255.	0.7	2
50	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.3	141